710 Medtronic Parkway, NE
Medtronic, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world.
Founders: Earl Bakken and Palmer Hermundlie
CEO: Omar Ishrak
CFO: Karen Parkhill
CSO (Scientific): Richard Kuntz
Please click here for Medtronic job opportunities.
Tweets by Medtronic
2198 articles with Medtronic
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the Morgan Stanley 18th Annual Global Healthcare Conference on Monday, September 14, 2020.
PRODIGY Study Provides First Validated Risk Prediction Tool to Guide Continuous Monitoring for Opioid-Induced Respiratory Depression (OIRD) OIRD Occurred in 46% of Patients Studied Patients with Respiratory Depression Are 37% More Likely to Experience an Adverse Event and Require Longer Hospital Stays DUBLIN , Sept. 10, 2020 /PRNewswire/ -- Medtronic plc (NYSE:
Medtronic EVP & CFO Karen L. Parkhill To Participate in the Wells Fargo Securities 2020 Virtual Healthcare Conference
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Wells Fargo Securities 2020 Virtual Healthcare Conference on Thursday, September 10, 2020 . Karen Parkhill , executive vice president and chief financial officer of Medtronic, will answer questions about the company begin
Medtronic Announces FDA Approval for MiniMed™ 770G Insulin Pump System with Smartphone Connectivity for People with Type 1 Diabetes
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 770G hybrid closed loop system.
ESC Congress: New Research Highlights First-Line Use of Cryoablation as Highly Effective, and with Improved Quality of Life Scores
Medtronic plc announced financial results for its first quarter of fiscal year 2021, which ended July 31, 2020.
Medtronic plc announced that its Board of Directors appointed Kevin Lofton to the Board as an independent director, effective September 15, 2020.
The board of directors of Medtronic plc on Friday, August 21, 2020, approved the fiscal year 2021 second quarter cash dividend of $0.58 per ordinary share, representing a 7 percent increase over the prior year.
Medtronic Evolut TAVR System Receives Updated U.S. Labeling Revising Precaution for Treatment of Low-Risk Patients with Bicuspid Aortic Stenosis
Revised Commercial Labeling Broadens Patient Population Who May be Candidates for Transcatheter Aortic Valve Replacement
ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and Non-Obstructive Urinary Retention DUBLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has begun recruitment of the prospective, multicenter, global, post-market study of the InterStim™ Micro system for sacral neuromodula
Medtronic plc (NYSE:MDT) announced today that it will report financial results for its first quarter of fiscal year 2021 on Tuesday, August 25, 2020. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at http://newsroom.medtronic.com . The news release will include summary financial information for the company’s first quarter of fiscal year 2021, which ended on Friday, July 31, 2020. Medtroni
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of privately-held Companion Medical, manufacturer of InPen — the only U.S. FDA-cleared smart insulin pen system paired with an integrated diabetes management app on the market. The addition of Companion Medical’s In
First Patient Receives New Sacral Neuromodulation Device Implant at Cleveland Clinic
Medtronic Expands Leadership in Treating Bladder and Bowel Control Conditions with Two New FDA-Approved Products: InterStim™ Micro Neurostimulator and InterStim™ SureScan™ MRI Leads
World’s Smallest Rechargeable Bladder/Bowel Control System — InterStim Micro — Features Trusted MRI Technology for Full-Body 1.5 and 3 Tesla MRI Scans
Medtronic Will Become the First Company to Offer an Integrated Solution Including Artificial Intelligence-Driven Surgical Planning, Personalized Spinal Implants and Robotic Assisted Surgery
Blackstone Life Sciences has already invested and committed nearly $1 billion from this fund over the past three months, demonstrating strong demand for the strategy
Medtronic plc (NYSE:MDT) and Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes. Cross-licensing each other’s patent portfolios enables both companies to focus on helping people with diabetes through innovation of future products and services, while avoiding the distraction of potential
Medtronic Introduces MiniMed™ Mio™ Advance Infusion Set Enabling Fewer Insertion Steps for People with Diabetes in the U.S.
Medtronic plc (NYSE:MDT), the global leader in medical technology, today introduced the MiniMed™ Mio™ Advance infusion set to all Medtronic insulin pump customers in the United States. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed™ portfolio of infusion sets and gives people using insulin pumps an optimal user experience with fewer steps 1 . The MiniMed Mio Advance infusion set is inserted in only four steps — individ
Next Generation ICM Offers Remote Programming with Improved Longevity and Enhanced Accuracy DUBLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE ( Conformité Européenne ) Mark approval for its LINQ II™ insertable cardiac monitor (ICM) with remote programming, which enables clinicians to optimize device settings without the need for patients to ret
Medtronic Begins Real-World Post-Market Study of the Valiant Navion Thoracic Stent Graft System in Patients with Thoracic Aortic Dissection
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the start of a prospective, observational, global, multi-center, real-world, post-market study to evaluate the safety and effectiveness of the Valiant Navion™ Thoracic Stent Graft System in the treatment of thoracic aort